Navigation Links
Pharmacopeia Nominates Novel Chemokine Receptor Antagonist for Development
Date:2/11/2008

.

In addition, Pharmacopeia announced that enrollment in its ongoing Phase 2a PS433540 (DARA) clinical trial in subjects with Stage I and Stage II hypertension is progressing well. The trial remains on schedule with results expected in the second quarter of 2008.

PS433540 is a dual-acting angiotensin (AII) and endothelin (ET1) receptor antagonist (DARA) that is being developed as a potential treatment for hypertension and diabetic nephropathy. PS433540, the first and only DARA compound in development, possesses two clinically validated mechanisms of action in a single compound. There is considerable preclinical and initial clinical data suggesting that compared to either agent alone, simultaneously blocking the actions of both AII and ET1 may provide significantly improved treatment options for several cardiovascular diseases.

About Pharmacopeia

Pharmacopeia is a clinical development stage biopharmaceutical company dedicated to discovering and developing novel small molecule therapeutics to address significant medical needs. The company has a broad portfolio of clinical and preclinical candidates under development internally or by partners including seven clinical compounds in Phase 2 or Phase 1 development addressing multiple indications including hypertension, diabetic nephropathy, muscle wasting, inflammation and respiratory disease. The company is leveraging its fully integrated drug discovery platform to sustain the growth of its development pipeline. Pharmacopeia has established strategic agreements with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb, Celgene, Cephalon, GlaxoSmithKline, Schering-Plough, and Wyeth Pharmaceuticals. For more information please visit the company's website at http://www.pharmacopeia.com.

Contact:

Amy P. Sharpless

Corporate Communications

Pharmacopeia, Inc.

609-452-3643

'/>"/>

SOURCE Pharmacopeia
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmacopeia to Present at BIO CEO & Investor Conference 2008
2. Pharmacopeia Announces Additional Positive Findings from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
3. Pharmacopeia Announces Third Quarter 2007 Financial Results
4. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
5. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
6. Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA)
7. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
8. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
9. BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R)
10. Novel Small Molecule Therapy Shows Benefit for Anemic Patients Via Hydration of Red Blood Cells
11. CeNeRx BioPharma Announces Successful Completion of Phase l Clinical Program for Novel Antidepressant Agent Tyrima(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... -- Sysmex America, Inc., a global leader in medical diagnostic ... exhibit booth during the American Association for Clinical ... in Chicago , July 27 through ... excited to exhibit at AACC this year, because it,s ... continue the dialogue on how to best meet the ...
(Date:7/29/2014)... Mass., July 29, 2014 Cynosure, Inc. ... markets laser- and light-based aesthetic treatment systems for high-volume ... ended June 30, 2014. Second-quarter 2014 financial results incorporate ... on June 24, 2013. Second-Quarter ... increased 45% to $72.6 million , Non-GAAP net ...
(Date:7/29/2014)... -- Apex Medical Corporation (Apex, TWSE: 4106), a leading player ... that it is appealing the judgment of the Regional Court ... that found the headgear of certain mask models ... invalidity challenges against various ResMed patents in major countries. Apex ... junk patents. ResMed filed the lawsuit with ...
Breaking Medicine Technology:New Product Offerings Highlight Sysmex's Presence at 2014 AACC in Chicago 2New Product Offerings Highlight Sysmex's Presence at 2014 AACC in Chicago 3Cynosure Reports Second-Quarter 2014 Financial Results 2Cynosure Reports Second-Quarter 2014 Financial Results 3Cynosure Reports Second-Quarter 2014 Financial Results 4Cynosure Reports Second-Quarter 2014 Financial Results 5Cynosure Reports Second-Quarter 2014 Financial Results 6Cynosure Reports Second-Quarter 2014 Financial Results 7Cynosure Reports Second-Quarter 2014 Financial Results 8Cynosure Reports Second-Quarter 2014 Financial Results 9Cynosure Reports Second-Quarter 2014 Financial Results 10Cynosure Reports Second-Quarter 2014 Financial Results 11Cynosure Reports Second-Quarter 2014 Financial Results 12Apex Continues Fighting Against Patents to Free Up Competition 2
... Oct. 9 Vical Incorporated,(Nasdaq: VICL ) ... mice demonstrated,the potential of its patented Vaxfectin(TM) adjuvant ... protein-based H5N1 pandemic influenza vaccine,currently stockpiled by the ... limited vaccine supplies to protect the greatest,number of ...
... Oct. 9 The Wellion Linus Blood Glucose,Monitoring ... recently received certification by the Netherlands Organization,for Applied ... group,founded in 1932 that thoroughly tests and inspects ... the CE Marking. "Receiving the TNO approval ...
Cached Medicine Technology:Vical Demonstrates Dose-sparing of Protein-based H5N1 Influenza Vaccine With Vaxfectin(TM) Adjuvant 2Vical Demonstrates Dose-sparing of Protein-based H5N1 Influenza Vaccine With Vaxfectin(TM) Adjuvant 3Vical Demonstrates Dose-sparing of Protein-based H5N1 Influenza Vaccine With Vaxfectin(TM) Adjuvant 4WaveSense Blood Glucose Meter One of Few Brands to Pass Rigorous TNO Tests 2
(Date:7/29/2014)... HealthDay Reporter TUESDAY, July 29, ... a task, various brain connections fire up. But scans ... autism, according to a small new study. Moreover, ... less of this "brain flexibility," the researchers found. ... children with autism are faced with new situations," said ...
(Date:7/29/2014)... Diego CA (PRWEB) July 29, 2014 As ... is working with its partners to both purchase critical emergency ... from the US to Liberia. These supplies will contain materials ... impacting the most heavily populated areas of the country. ... very involved in the response to the Ebola outbreak in ...
(Date:7/29/2014)... 2014) Using quality improvement measures in eight of ... Disease Study Group, researchers have found a way to ... contrast dye. , Currently, 7-15 percent of these patients ... up with kidney injury, which can result in death ... or permanent dialysis, says a study published in the ...
(Date:7/29/2014)... York, New York (PRWEB) July 29, 2014 ... on behalf of individuals who allegedly suffered serious ... medications continue to move forward in a multidistrict ... of Pennsylvania, Bernstein Liebhard LLP reports. According to ... revised certain deadlines pertaining to bellwether case ...
(Date:7/29/2014)... By Alan Mozes ... -- Treating certain adult autism patients with just a single ... judge facial expressions and emotions, Japanese researchers report. Known ... a role in emotional bonding between lovers, and between mothers ... neural activity in a key area of the brain that ...
Breaking Medicine News(10 mins):Health News:Less Flexibility Seen in Brain Wiring of Kids With Autism: Study 2Health News:Less Flexibility Seen in Brain Wiring of Kids With Autism: Study 3Health News:PCI Responds to Ebola Outbreak in Liberia with Supplies, Awareness Campaigns 2Health News:PCI Responds to Ebola Outbreak in Liberia with Supplies, Awareness Campaigns 3Health News:Reducing kidney injury using a quality improvement method 2Health News:Tylenol Lawsuit News: Federal Court Overseeing Tylenol Liver Damage Claims Sets New Deadlines Pertaining to Discovery, Bellwether Trials, Bernstein Liebhard LLP Reports 2Health News:Tylenol Lawsuit News: Federal Court Overseeing Tylenol Liver Damage Claims Sets New Deadlines Pertaining to Discovery, Bellwether Trials, Bernstein Liebhard LLP Reports 3Health News:Tylenol Lawsuit News: Federal Court Overseeing Tylenol Liver Damage Claims Sets New Deadlines Pertaining to Discovery, Bellwether Trials, Bernstein Liebhard LLP Reports 4Health News:'Love Hormone' Oxytocin May Help Some With Autism 2Health News:'Love Hormone' Oxytocin May Help Some With Autism 3
... continue to fight the battle of the bulge. Now they,ll ... developed a new method to look at how fat cells ... to mechanical loads. This might be the key to ... fat cells, the holy grail of weight loss researchers, says ...
... , MONDAY, Nov. 22 (HealthDay News) -- The pain ... have foot, elbow and lower back pain, a new study ... knee osteoarthritis (OA) patients, aged 45 to 79, about pain ... knee, ankle or foot. Low back pain was significantly ...
... today estimates that the global initiative to eradicate polio ... if transmission of wild polioviruses is interrupted within the ... evaluation of the benefits and costs of the Global ... by the global health community. The study comes at ...
... Dr. Oliver Daumke of the Max Delbrck Center for ... Early Excellence in Science Award 2010" in the biology ... for his contributions to the understanding of the structure ... Berlin. Together with him, two other scientists, Professor Nicolai ...
... , SATURDAY, Nov. 20 (HealthDay News) -- ... dialysis treatments typically prescribed had significantly better heart function, ... indicates. The finding stems from an analysis that ... -- three dialysis treatments per week, for three to ...
... , MONDAY, Nov. 22 (HealthDay News) -- If teens, ... could be compromised, a new study suggests. Teens ... providers for fear of being judged, and are reluctant ... to researchers at Cincinnati Children,s Hospital Medical Center. ...
Cached Medicine News:Health News:Putting the squeeze on fat cells 2Health News:Economic benefits of the global polio eradication initiative estimated at $40-50 billion 2Health News:Doubling Frequency of Dialysis May Help Kidney Failure Patients 2Health News:Doubling Frequency of Dialysis May Help Kidney Failure Patients 3Health News:For Teens, Privacy May Trump Health Care 2
... Steri-Cath™ Closed Ventilation Suction Systems Reduce ... Constant Patient Ventilation, ,Cost-effective and ... Ventilation Suction Systems reduces the risk ... contact with the catheter, Steri-Cath™ maintains ...
... Catheters are available in two ... DeLee tip with staggered eyes, ... Two types of catheter valve ... easy fingertip control with virtually ...
... Catheters are available in two ... DeLee tip with staggered eyes, ... Two types of catheter valve ... easy fingertip control with virtually ...
... Our Tri-Flo® suction catheter design ... to your patients while still providing ... pediatric catheters (5/6, 8 or 10 ... facilitate proper catheter placement. Our complete ...
Medicine Products: